Galantamine: anti-Diabetic Effect Mediated By Anti- Oxidant/Inflammatory/Apoptotic Effects And Improvement of Insulin And Wnt/β-Catenin Signaling Pathways

      The cholinergic anti-inflammatory pathway is one of the putative biochemical pathways that link diabetes with Alzheimer disease. Hence, here we aimed to verify the potential antidiabetic effect and to unveil the possible mechanisms of galantamine, a clinically approved acetylcholinesterase (AChE) inhibitor used in Alzheimer disease. Additionally, we evaluated its effect as an add-on therapy with vildagliptin.
      To read this article in full you will need to make a payment
      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect